Page last updated: 2024-11-12
cgs 21680a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10256643 |
| CHEMBL ID | 537419 |
| MeSH ID | M0169943 |
Synonyms (36)
| Synonym |
|---|
| MLS002153401 |
| cgs 21680 (hydrochloride) |
| HY-13201A |
| REGID_FOR_CID_10256643 |
| MLS001056776 |
| smr000058796 |
| cgs 21680 hydrochloride |
| 2-p-(2-carboxyethyl)phenethylamino-5'-n-ethylcarboxamidoadenosine hydrochloride |
| 3-{4-[2-({6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl]-9h-purin-2-yl}amino)ethyl]phenyl}propanoic acid hydrochloride |
| cgs 21680a |
| 124431-80-7 |
| hydrochloride salt of (2-(p-2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine |
| benzenepropanoic acid, 4-(2-((6-amino-9-(n-ethyl-beta-d-ribofuranuronamidosyl)-9h-purin-2-yl)amino)ethyl)-, monohydrochloride |
| CHEMBL537419 |
| BCP9000512 |
| 3-(4-(2-(6-amino-9-((2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9h-purin-2-ylamino)ethyl)phenyl)propanoic acid hydrochloride |
| CS-0425 |
| S2153 , |
| MLS006011122 |
| 4-[2-[[6-amino-9-(n-ethyl-?-d-ribofuranuronamidosyl)-9h-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride |
| AC-32733 |
| AKOS024456361 |
| 3-(4-(2-((6-amino-9-((2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9h-purin-2-yl)amino)ethyl)phenyl)propanoic acid hydrochloride |
| cgs 21680 hcl |
| DTXSID2040999 |
| mfcd00078573 |
| J-005077 |
| AS-75112 |
| 3-{4-[2-({6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-9h-purin-2-yl}amino)ethyl]phenyl}propanoic acid hydrochloride |
| 3-[4-[2-[[6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid;hydrochloride |
| 3-(4-(2-((6-amino-9-((2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydro-furan-2-yl)-9h-purin-2-yl)amino)ethyl)phenyl)propanoic acid hydrochloride |
| EX-A2473 |
| cgs21680 hcl |
| cgs21680hydrochloride |
| benzenepropanoic acid, 4-[2-[[6-amino-9-(n-ethyl-beta-d-ribofuranuronamidosyl)-9h-purin-2-yl]amino]ethyl]-, hydrochloride (1:1) |
| CCG-269942 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (6)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 112.2020 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.7079 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 0.8609 | 0.0003 | 6.2102 | 28.8403 | AID504840; AID588401 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||